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or targeted therapeutic agents at timeof recur-
rence. Therefore, development of a tissue and
blood (serum, plasma, and circulating cells)
bank with specimens obtained in clinical tri-
als, including detailed prospective collected
clinical data, is of the utmost importance.
This new phase of target profiling and
agent-specific profiling will probably require
an algorithm that would include genomic,
proteomic, clinical, and imaging factors.
Patients with early-stage NSCLC will be
assigned to particular drugs on the basis of
the molecular characteristics of their tumors.
Then the development of drugs for the treat-
ment of NSCLC will be focused on person-
alized therapy.
Figure 1 outlines a possible application
of molecular biology to refine the assess-
ment of risk and guide the use of adjuvant
chemotherapy in stage IA NSCLC.
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Figure 1. Application of molecular biol-
ogy to refine the assessment of risk and
guide the use of adjuvant chemotherapy
in stage IA non–small cell lung cancer
(NSCLC).
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To the Editor:
It is with great interest that we read the article
entitled ‘‘Thoracoscore predicts midterm
mortality in patients undergoing thoracic
surgery.’’1 The authors’ findings and conclu-
sions concur perfectly with those of our
initial main work, which first created and
proposed the use of the Thoracoscore.2
However, we would like to emphasize 2
points that we consider to be important.
First, one of our concerns is the reliability
of anymodification in the French scoring sys-
tem (Thoracoscore), as was done with the
dyspnea score in the present study. This point
is particularly crucial. Effectively, our initial
aim was to develop a self-assessment system
based on a large database reflecting current
practices in adult thoracic surgery. Nine pre-
dictors were selected from the database. Their
definitions, which are consistent throughout
the world and particularly in North American
systems, were objective enough to developvascular Surgery c July 2008a reliable scoring system that could be used
by all thoracic surgeons and for all types of
thoracic procedures. This is why we think
that theThoracoscore canbeusedasa relevant
yardstick for mortality. Moreover, the French
scoring system, built onwell-defined risk fac-
tors, is alsouser friendlyand imposesminimal
demands on medical time. At this point,
a word of caution is essential: the condition
under which such a system is used needs to
be considered. The Thoracoscore was con-
structed so as to deal with the problem of
a missing item. Indeed, in the case of 1 or
more items missing from the 9 predictors se-
lected, the Thoracoscore gives a range (mini-
mum and maximum values) of estimated
mortality rather than a percentage of predic-
tivemortality. Thus it can be used easily, as is.
Second, why is the Thoracoscore a reli-
able tool, and how can it be used world-
wide? The Thoracoscore is reliable
because it comes from a national electronic
prospective database created by a national
society of thoracic and cardiovascular sur-
gery. Indeed, the French database Epithor,
created in 2002 on behalf of the French So-
ciety of Thoracic and Cardiovascular Sur-
gery, includes anonymous information
from two thirds of all thoracic surgery pro-
cedures performed in France each year
(.60,000 from 59 centers: 37 public and
15 private). Each center is free to compare
its statistics and results with the national
means. It can also be used to register pa-
tients for administrative hospital files.
In addition, Epithor is now mandatory for
the accreditation of thoracic surgery depart-
ments. Therefore the Thoracoscore tool can
be transposed to any organization (country/
Letters to the Editordepartment) with an exhaustive database
controlled by a scientific committee.
Furthermore, thoracic surgical education
has become a priority within the French
Society of Thoracic and Cardiovascular
Surgery, thanks to the French College of
Thoracic and Cardiovascular Surgery (eg,
a prerequisite for diplomas, board certifica-
tion, continuing medical education, and
postgraduate course), and the French pro-
gram for quality of care assessment for sur-
gical procedures, to which Epithor belongs,
in adult thoracic surgery is a now a reality
(ad hoc committees for audit and clinical rel-
evance and for database).Finally, we are certain that much is to be
gained from external validations, such as the
one done at St Luke’s–Roosevelt Hospital
Center of Columbia University. To reach
an international consensus through such val-
idations would greatly enhance the strength
of the Thoracoscore.
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